BRUSSELS, Belgium and MELBOURNE, Australia, 20th of April 2021 – The Oncidium foundation, a non-profit organisation created to promote and support the development of radiopharmaceuticals for better patient access, and Telix Pharmaceuticals Limited (‘Telix’), a Radiopharmaceutical company developing diagnostic and therapeutic products (‘theranostics’) using Molecularly Targeted Radiation (MTR), are pleased to announce the launch of the NOBLE Registry, an international clinical collaboration for the development of 99mTc-iPSMA SPECT Imaging for prostate cancer, and the dosing of the first patient at the University College Hospital, Ibadan, Nigeria.
